The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.

Vincenzo Davide Palumbo, Marcello Romeo, Antonella Marino Gammazza, Francesco Carini, Provvidenza Damiani, Giuseppe Damiano, Salvatore Buscemi, Attilio Ignazio Lo Monte, Alice Gerges-Geagea, Abdo Jurjus, Giovanni Tomasello

Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2017;160(3):372-7

PMID: 27623957

Free Full Text on Palacky University Olomouc View on PubMed

Abstract

AIM

Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity.

METHOD

Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index.

RESULTS

All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment.

CONCLUSIONS

A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

Address: Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.; Department of Surgical, Oncological and Stomatological Disciplines, School of Medicine, University of Palermo, Palermo, Italy.; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy.; Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy.; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy.; P. Giaccone University Hospital, Palermo, Italy.; P. Giaccone University Hospital, Palermo, Italy.; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy.; Department of Anatomy, Cell Biology and Physiology, School of Medidcine, Aamerican University of Beirut, Beirut, Lebanon.; Department of Anatomy, Cell Biology and Physiology, School of Medidcine, Aamerican University of Beirut, Beirut, Lebanon.; Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy.; P. Giaccone University Hospital, Palermo, Italy.

DOI: 10.5507/bp.2016.044

Link outs

Free resources

Full Text Sources:

http://biomed.papers.upol.cz/doi/10.5507/bp.2016.0...

Medical:

https://medlineplus.gov/ulcerativecolitis.html

Other Literature Sources:

MeSH Terms: Adult, Aged, Analysis of Variance, Anti-Inflammatory Agents, Non-Steroidal, Bifidobacterium bifidum, Colitis, Ulcerative, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Lactobacillus acidophilus, Ligilactobacillus salivarius, Male, Mesalamine, Middle Aged, Probiotics, Treatment Outcome